Shilpa Medicare Experiences Revision in Its Score Following Strong December 2024 Quarter Performance

Shilpa Medicare has reported a robust financial performance for the December 2024 quarter, showcasing significant growth across key metrics. The company has experienced a notable increase in its score, reflecting a positive adjustment in evaluation over the past three months. Among the highlights, Shilpa Medicare achieved an impressive operating profit to interest ratio, marking a peak of 6.87 times. The profit before tax, excluding other income, surged to Rs 40.48 crore, demonstrating a remarkable growth rate of 96.6%. Additionally, the profit after tax reached Rs 31.78 crore, which represents a substantial increase of 128.4% compared to previous periods. The company also excelled in operational efficiency, with an inventory turnover ratio hitting 3.72 times and a debt-equity ratio at a low of 0.21 times, indicating strong financial health. Furthermore, the debtors turnover ratio stood at 3.38 times, underscoring effective management of receivables. As Shilpa Medicare continues to navigate the competitive landscape of the pharmaceuticals and drugs industry, its recent performance positions it favorably for future growth and investor interest.